However, the weight loss maker, which also sells semaglutide for type 2 diabetes under the brand name Ozempic, has been under scrutiny for its pricing of Wegovy, which stands at $1,349 for a pack of four injection pens in the U.S
Prior authorization and step therapy protocols, as well as body mass index and medical conditions-based criteria, remain some of the major factors affecting patients access to reimbursement
* **Formulary Restrictions:** The drug might not be on your plans formulary (list of covered drugs), or it might be placed on a high tier with a large co-pay/co-insurance
1 Current guidelines indicate that the main goal of T2D treatment is to prevent or delay diabetes-related complications, which are mainly cardiovascular, and to maintain quality of life
Comprehensive lab work is ordered
The favorable effects of tirzepatide on myocardial injury may contribute to reduced risk for worsening HF seen in the SUMMIT trial 16